OPGx-001

· Opus Genetics, Inc

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OPGx-001, covering 2026-02-19 to 2026-02-19. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients [Phase 1, Phase 2]

See pricing